SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Cancer Metabolism
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1583592
This article is part of the Research TopicSynthetic Biology and Metabolomics: Novel Insight in Oncology ResearchView all 5 articles
Incidence of Thyroid Adverse Events Following Immune Checkpoint Inhibitor Treatment in Patients with Baseline Positive Thyroid Antibodies: A Systematic Review and Meta-analysis
Provisionally accepted
- Huangshi Central Hospital, Huangshi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: To systematically evaluate the incidence of thyroid adverse events in patients with baseline positive thyroid antibodies following treatment with immune checkpoint inhibitors (ICIs). Methods: In this systematic review and meta-analysis, we utilized PubMed, Embase, and Cochrane Library databases to identify studies that detail the thyroid immune-related adverse events (irAEs) among cancer patients undergoing treatment with ICIs. Literature was screened according to inclusion and exclusion criteria, and data were extracted. Meta-analysis was conducted using RevMan 5.4 and Stata 16.0 software, with adherence to PRISMA 2020 guidelines. Results: A total of 13 studies involving 2,059 patients treated with ICIs for malignancies were included, with 594 cases of thyroid irAEs reported post-treatment. Meta-analysis revealed that the incidence of thyroid irAEs in patients with baseline positive thyroid antibodies was 66.7% (95% CI: 45.1%, 85.5%; Z=7.825, p<0.001). Subgroup analysis indicated that heterogeneity was influenced by geographic region, tumor type, and study type. In an exploratory analysis of 4 studies, thyroglobulin antibody (TgAb) positivity showed a numerically higher risk (but statistically non-significant) of thyroid irAEs compared to thyroid peroxidase antibody (TPOAb) positivity (OR=1.83, 95% CI: 0.87 -3.85; Z=1.58, p=0.114), but the small number of studies precludes definitive conclusions. Conclusion: Patients with baseline positive thyroid antibodies experience a higher incidence of thyroid irAEs following ICI treatment. In comparison to TPOAb, baseline TgAb positivity showed a non-significant trend toward higher thyroid irAE risk (based on limited studies), but further evidence is needed to confirm this relationship.
Keywords: immune checkpoint inhibitors, Thyroid antibodies, Thyroglobulin antibody, Thyroid peroxidase antibody, Thyroid-related adverse events, thyroid dysfunction
Received: 26 Feb 2025; Accepted: 08 Jul 2025.
Copyright: © 2025 Yu, Chen, Hu, Chen and Ming. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yuanhao Chen, Huangshi Central Hospital, Huangshi, China
Hui Ming, Huangshi Central Hospital, Huangshi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.